Parkinson’s Disease and Alzheimer’s Pathology in Women

Key Takeaways

• • Women with Parkinson’s disease showed significantly greater amyloid plaque burden than men in an autopsy-confirmed study.
  • Female participants were more than twice as likely to have high Alzheimer ‘s-related amyloid pathology after adjusting for age and APOE ε4 status.
  • Despite increased plaque burden, men and women demonstrated similar cognitive performance and rates of Alzheimer’s dementia.
  • Findings highlight the need for further research into sex differences in Parkinson’s disease and Alzheimer ‘s-related brain pathology.
  • For More Updates in Neurology, register for the American Neurology Summit 2026 (ANS2026). 
  • For more Updates in women’s health, register for the HerHealth2026 CME Conference

Women with Parkinson’s Disease Show Higher Alzheimer’s Pathology

As researchers continue to investigate the relationship between Parkinson’s disease and Alzheimer’s pathology, a new study presented at the European Academy of Neurology (EAN) Congress 2026 suggests that women with Parkinson’s disease may experience a greater accumulation of Alzheimer ‘s-related brain changes than men. The findings provide valuable insights for neurologists, geriatricians, and healthcare professionals seeking to better understand cognitive risk in neurodegenerative disorders.

Researchers from Mayo Clinic Arizona examined data from 230 autopsy-confirmed Parkinson’s disease cases enrolled in the Arizona Study of Aging and Neurodegenerative Disorders and the Brain and Body Donation Program. Participants received annual neurological assessments during life, followed by comprehensive neuropathological evaluations after death.

The investigation focused on amyloid plaque burden, one of the defining pathological features of Alzheimer’s disease, to determine whether biological sex influences Alzheimer ‘s-related changes in patients with Parkinson’s disease.

Why Do Women with Parkinson’s Disease Have Greater Alzheimer’s Pathology?

The study revealed notable sex-based differences in Alzheimer ‘s-related brain pathology.

Women demonstrated significantly higher cortical amyloid plaque scores than men, along with greater neuritic plaque density. More than 56% of female participants had a high amyloid plaque burden compared with nearly 40% of men. Even after adjusting for age at death and the presence of the APOE ε4 genetic risk factor, women remained more than twice as likely to exhibit substantial amyloid plaque accumulation.

These findings suggest that women may have a greater biological susceptibility to amyloid-driven neurodegeneration in the setting of Parkinson’s disease, mirroring observations reported in Alzheimer’s disease research.

The investigators believe these results strengthen the growing evidence that sex may influence the underlying neuropathology of neurodegenerative diseases and should be considered in future research and clinical investigations.

Can Higher Amyloid Plaque Burden Affect Cognitive Function?

One of the most intriguing findings was that increased amyloid plaque accumulation did not correspond to poorer clinical outcomes.

Researchers found no significant differences between men and women in cognitive testing results or rates of Alzheimer’s dementia despite the higher pathological burden observed in women.

Lead investigator Dr. Erika Driver-Dunckley noted that larger clinicopathological studies may be needed to determine whether cognitive differences emerge with larger patient populations or over longer follow-up periods.

The findings also raise important questions about why substantial Alzheimer’s pathology does not always translate into measurable cognitive impairment. Investigators suggest that additional biological mechanisms, including sex-specific factors, resilience pathways, and disease interactions, deserve closer examination.

For More Updates in Neurology, register for American Neurology Summit 2026 (ANS2026), Also, for more Updates in women’s health, register for HerHealth2026 

For healthcare professionals managing patients with Parkinson’s disease, these results reinforce the importance of recognizing potential sex differences in neurodegenerative pathology while supporting continued research into personalized diagnostic strategies and future therapeutic approaches.

Source:

European Academy of Neurology (EAN) Congress 2026